Uncovering Value: Three Fresh 5-Star Stocks Enter Morningstar's Spotlight

In the dynamic world of stock markets, identifying genuine value can often feel like searching for a needle in a haystack. But thankfully, resources like Morningstar are here to lend a hand, especially when the broader market takes a bit of a breather. As of mid-October 2026, with the Morningstar US Total Market Index having nudged down 2.06% over the past week, analysts have highlighted three new companies earning that coveted 5-star rating, suggesting they're significantly undervalued and might just be ripe for the picking.

It’s always fascinating to see which companies make the cut, especially when the overall U.S. stock market itself is considered moderately undervalued, sitting at about an 8% discount to its fair value estimate. This week, we're looking at a trio that has moved into the top tier of Morningstar's ratings. Let's dive a little deeper into these intriguing selections:

First up is PayPay Corp ADR - Sponsor (PAYP). This player in the Software - Infrastructure space has earned a full five stars from Morningstar. Analysts peg its fair value at $26.00, and here’s the kicker: it’s currently trading at a roughly 40% discount to that estimate. Now, it does carry a 'High' uncertainty rating, which is certainly something to consider, but its 'Narrow' economic moat suggests it possesses some sustainable competitive advantages. That kind of discount, coupled with a moat, really makes one pause and think.

Next on our list is CRISPR Therapeutics AG (CRSP), a name that probably rings a bell for anyone following the Biotechnology sector. This company also secured a 5-star rating, with a fair value estimate of $106.00. What's truly striking here is the massive discount—a whopping 54% below its fair value! Biotech can be a wild ride, and CRSP reflects that with a 'Very High' uncertainty rating and, perhaps not surprisingly, 'None' for its economic moat. But for investors comfortable with higher risk in pursuit of potentially substantial rewards, a 54% discount in such an innovative field could be incredibly compelling.

Rounding out our trio is Cogent Communications Holdings Inc (CCOI), operating in the Telecom Services industry. Like its peers this week, Cogent has achieved a 5-star rating. Morningstar estimates its fair value at $17.00, and it's currently trading at a hefty 53% discount to that figure. Similar to CRISPR, it comes with a 'Very High' uncertainty rating, but it does manage to hold a 'Narrow' economic moat, offering a bit more stability than pure biotech. Seeing two companies with such deep discounts this week truly underscores the market's current state of moderate undervaluation.

Beyond these specific picks, it’s worth noting the broader landscape Morningstar's analysts are observing. Out of 869 US-listed stocks they cover, 43% are currently undervalued, 40% are deemed fairly valued, and only 17% are overvalued. This recent volatility seems to have shifted things around a bit. For instance, while 10 stocks moved into the 4-star (undervalued) category, and our three stars here jumped to 5, there were also 5 stocks that slipped from 5-star to 4-star, and 30 that are simply no longer considered undervalued. It just goes to show how quickly things can change!

A quick refresher on Morningstar's stock ratings: they’re designed to help investors spot undervalued or overvalued opportunities. A stock’s price, its fair value estimate, and its Uncertainty Rating all factor into this calculation. Generally, 4 or 5 stars signal an undervalued stock, 3 stars mean it’s fairly valued, and 1 or 2 stars indicate it's overvalued. The Uncertainty Rating, as seen with our featured stocks, provides crucial context about the predictability of a company’s future cash flows—something to always keep in mind when evaluating potential investments.

So, even when the market index is a bit down, opportunities often emerge for those willing to look a little closer. These three new 5-star stocks from Morningstar certainly offer some interesting food for thought for investors keen on finding value in today’s market.